This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Prophylactic (preventative) measures against development of mountain sickness

Authoring team

It is advised that climbers should acclimatise if climbing to high altitude.

  • if above 3000m (10,000 feet), no more than 300m (1000 feet) should be climbed per 24 hour period (1)
    • if a climber develops symptoms of mild altitude sickness then he/she should rest for 24 hours at that altitude
    • if a climber has more severe symptoms then he/she must descend to the last altitude at which they felt well. This should occur whether or not they use drugs
    • if rapid ascent is unavoidable then acetozolamide is beneficial
    • a rest day every 3 days or 1000 m

Prevention of acute mountain sickness (AMS) (2)

  • acetazolamide can be used for preventing AMS according to the National Travel and Health Network Centre and Fit For Travel recommendations (not licensed for this this indication)
  • acetazolamide prevents AMS by mimicking the body naturally adjusting to a change in environment
  • a Cochrane review demonstrated acetazolamide reduced the risk of AMS vs placebo by a factor of 0.47 (n=2,301, 16 studies). Acetazolamide was administered one to five days prior to ascent with doses of up to 500mg/day to adults at risk of AMS

    • prescribing and dosing
      • use acetazolamide 125mg twice daily (off-label).
      • smaller doses of acetazolamide can be given by halving 250mg tablets which are scored.
      • prescribe acetazolamide one to two days before gradual ascent to high altitude and continue acetazolamide for at least two days after reaching the highest point.
      • advise people to take the second dose of acetazolamide at dinnertime rather than at bedtime as it is a diuretic.
      • trial acetazolamide for two days before ascent to high altitude because side effects can resemble the symptoms of AMS
      • check local guidelines for processes on prescribing acetazolamide for travel
    • cautions
      • take into account the contraindications and cautions of acetazolamide and check if it is appropriate for the person
      • avoid acetazolamide in people with a history of anaphylaxis or severe allergy to suphonamide as it is a sulphonamide derivative

  • the NHS review did not recommend any other medications for use in AMS prophylaxis
    • overall, evidence for the use of the medicines listed below to prevent AMS is inconclusive and for some, side effects are a concern:
      • aspirin
      • dexamethasone
        • Using dexamethasone has been suggested by some organisations to help prevent AMS. However, the Cochrane review (n=176) assessing four parallel studies comparing dexamethasone with placebo found dexamethasone does not prevent AMS at any dose and does not aid acclimatisation.
      • ibuprofen
      • iron supplements
      • magnesium citrate
      • spironolactone
      • sumatriptan

Notes:

  • if acetazolamide is used, treatment should be started at least one day before ascent and continued until adequate acclimatisation is judged to have occurred
    • side effects, which include paraesthesia and mild diuresis, are common but usually well tolerated
    • acetazolamide is a sulphonamide, and allergic reactions can occur
    • acetazolamide is not a substitute for acclimatisation

  • phosphodiesterase Inhibitors as prophylaxis for altitude sicknes: tadalafil and sildenafil (3)
    • because of its pulmonary vasodilatory effects, the phosphodiesterase inhibitor tadalafil can be used for prevention of high altitude pulmonary edema (HAPE)
      • it has been demonstrated that tadalafil prevents the disease in known HAPE-susceptible individuals. No studies have examined whether the drug can also be used to treat HAPE
      • although no systematic studies have examined whether sildenafil is effective in the prevention and treatment of HAPE, it is worth considering this medication as well because it has a similar mechanism of action and should exert a similar benefit as tadalafil and because there are reports of its use in clinical practice as treatment for HAPE or prevention in children with underlying cardiopulmonary disease and HAPE

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.